Following pressure, Biogen to start compassionate use program for ALS drug tofersen

Following pressure from individual patients and groups, Biogen (NASDAQ:BIIB) has agreed to start a compassionate use program for its experimental ALS (amyotrophic lateral sclerosis) drug tofersen.